National Institute on Drug Abuse; Notice of Meeting, 21526 [2024-06612]

Agencies

• DEPARTMENT OF HEALTH AND HUMAN SERVICES
• National Institutes of Health

[Federal Register Volume 89, Number 61 (Thursday, March 28, 2024)]
[Notices]
[Page 21526]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-06612]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of a meeting of the National Advisory 
Council on Drug Abuse.
    This will be a hybrid meeting held in-person and virtually and will 
be open to the public, as indicated below, with attendance limited to 
space available. Individuals who plan to attend in-person or view the 
virtual meeting and need special assistance such as sign language 
interpretation or other reasonable accommodations, should notify Dr. 
Jeanette Marketon via email at [email protected] five days in 
advance of the meeting. The open session of the meeting can be accessed 
from the NIH Videocast at the following link: https://videocast.nih.gov/.
    A portion of the meeting will be closed to the public in accordance 
with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), 
Title 5 U.S.C., as amended. The grant applications and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Advisory Council on Drug Abuse.
    Date: May 7, 2024.
    Closed: 10:30 a.m. to 11:45 a.m.
    Agenda: To review and evaluate grant applications.
    Open: 12:45 p.m. to 5:00 p.m.
    Agenda: Presentations and other business of the Council.
    Place: Neuroscience Center, Conference Room 1155/1145, National 
Institutes of Health, 6001 Executive Boulevard, Rockville, MD 20852 
(Hybrid Meeting).
    Contact Person: Susan R.B. Weiss, Ph.D., Director, Division of 
Extramural Research, Office of the Director, National Institute on 
Drug Abuse, NIH, Three White Flint North, RM 09D08, 11601 Landsdown 
Street, Bethesda, MD 20852, 301-443-6480, [email protected].
    Contact Person: Jeanette Marketon, Ph.D., PMP Director, Office 
of Extramural Policy. Division of Extramural Research, Office of 
Extramural Policy, National Institute on Drug Abuse, NIH, Three 
White Flint North, RM 09C71, 11601 Landsdown Street, Bethesda, MD 
20852, 301-443-5239, [email protected].

    Any interested person may file written comments with the committee 
by forwarding the statement to Dr. Jeanette Marketon via email at 
[email protected]. The statement should include the name, 
address, telephone number and when applicable, the business or 
professional affiliation of the interested person.
    In the interest of security, NIH has procedures at https://www.nih.gov/about-nih/visitor-information/campus-access-security for 
entrance into on-campus and off-campus facilities. All visitor 
vehicles, including taxicabs, hotel, and airport shuttles will be 
inspected before being allowed on campus. Visitors attending a meeting 
on campus or at an off-campus federal facility will be asked to show 
one form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their visit.
    Information is also available on the Institute's/Center's home 
page: www.drugabuse.gov/NACDA/NACDAHome.html, where an agenda and any 
additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Abuse Scientist Development Award for Clinicians, Scientist 
Development Awards, and Research Scientist Awards; 93.278, Drug 
Abuse National Research Service Awards for Research Training; 
93.279, Drug Abuse and Addiction Research Programs, National 
Institutes of Health, HHS)

    Dated: March 25, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-06612 Filed 3-27-24; 8:45 am]
BILLING CODE 4140-01-P